Epilepsy

Neurology News Network for the week ending November 23, 2019.

The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic detailed the transition patients and doctors make from the office to telemedicine.

SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.

The investigational new drug application for OWP Pharmaceuticals’ first-ever liquid formulation of topiramate, intended to offer a new delivery alternative for the therapy in epilepsy and migraine treatment, has been approved.

The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic discussed the advanced application of telemedicine at Cleveland Clinic.

SK Life Science’s investigational agent cenobamate has shown an ability to significantly reduce focal-onset seizures in doses of 100, 200, and 400-mg compared to placebo. An NDA was filed for the therapy in early 2019.

The director of the Epilepsy Center at Cleveland Clinic reviewed the role that wearable technology can play in detecting seizures in patients with epilepsy.

The director of the Epilepsy Center at Cleveland Clinic discussed why cannabidiol should be used cautiously in patients with epilepsy.

An automated deep neural network, SpikeNet, performed at or above the accuracy, sensitivity, and specificity of fellowship-trained clinical experts in identifying interictal epileptiform discharges.

Interictal epileptiform discharges on EEG readings had a positive predictive value of 77.3% and a negative predictive value of 70 %, with a sensitivity of detecting spikes prior to epilepsy of 85%.

The director of the Epilepsy Center at Cleveland Clinic explained why epilepsy surgery should be recommended and incorporated more.

An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.

The director of the Epilepsy Center and vice chair of Neurological Institute for Strategy and Development at Cleveland Clinic detailed how researchers are working to utilize a biomarker to enhance epilepsy surgery.

Study findings have shown sustained improvements in seizure-freedom rates and functional outcomes in a cohort of adults that mirror prior findings in pediatric populations.

An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.

The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic relayed his excitement for a new advanced imaging tool that could change how epilepsy specialists diagnose and treat the disease.

Imad Najm, MD, details how advanced telemedicine technology has created a paradigm shift in the way physicians see and treat patients at Cleveland Clinic and around the world.

UCB’s intranasal midazolam spray (Nayzilam), an FDA-approved therapy for seizure clusters, has shown success and rapid efficacy in status epilepticus, with treatment effect occurring approximately 4 to 5 minutes post-administration.

The director of the Epilepsy Center at Cleveland Clinic spoke about the challenges faced when identifying focal cortical dysplasia.

Study results suggest that as many as 20% of patients may be nonadherent to medication regimens, with youth having the strongest association with intentional nonadherence.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.